Satellos Bioscience Inc. Stock OTC Markets
Stocks
MSLE
CA80401L8033
Biotechnology & Medical Research
OTC Markets Traded|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
+6.50% | +111.33% |
| Market Cap | 183M 160M 147M 136M 256M 17.6B 262M 1.76B 693M 8.62B 686M 671M 29.67B | P/E 2026 * |
-4.98x | P/E 2027 * | -5.32x |
|---|---|---|---|---|---|
| Enterprise Value | 89.09M 77.85M 71.84M 66.22M 125M 8.58B 128M 859M 338M 4.2B 335M 327M 14.46B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
93.52% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Frank Gleeson
CEO | Chief Executive Officer | 70 | 2018-02-28 |
Michael Rudnicki
CTO | Chief Tech/Sci/R&D Officer | - | 2018-04-30 |
| Director of Finance/CFO | - | 2023-08-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Geoff MacKay
CHM | Chairman | 59 | 2018-06-30 |
Brian Bloom
BRD | Director/Board Member | 50 | 2018-02-28 |
Frank Gleeson
BRD | Director/Board Member | 70 | 2012-06-30 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +6.50% | - | - | 183M | |
| +0.21% | -0.79% | +56.02% | +57.39% | 53.83B | |
| +5.37% | +0.75% | +50.39% | +83.03% | 52.1B | |
| +0.21% | -0.37% | +5.79% | +410.73% | 23.48B | |
| +0.94% | +2.81% | -14.98% | -14.04% | 23.13B | |
| +3.46% | +0.79% | +34.01% | -4.47% | 19.36B | |
| -1.18% | -2.97% | +32.73% | -33.30% | 17.56B | |
| -1.67% | -8.56% | +163.95% | +284.69% | 15.2B | |
| +3.62% | -2.42% | +29.70% | +663.64% | 14.83B | |
| +0.67% | +0.51% | +27.26% | +183.47% | 14.06B | |
| Average | +1.15% | -2.44% | +42.76% | +181.24% | 25.95B | |
| Weighted average by Cap. | +1.70% | -2.34% | +42.73% | +140.48% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -48.32M -42.23M -38.97M -35.92M -67.7M -4.65B -69.2M -466M -183M -2.28B -181M -177M -7.85B | -56.57M -49.43M -45.62M -42.05M -79.25M -5.45B -81.01M -545M -214M -2.67B -212M -208M -9.18B |
| Net Debt | -93.65M -81.84M -75.52M -69.61M -131M -9.02B -134M -903M -355M -4.42B -352M -344M -15.21B | -111M -97.31M -89.79M -82.77M -156M -10.72B -159M -1.07B -422M -5.25B -418M -409M -18.08B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MSCL Stock
- MSLE Stock
Select your edition
All financial news and data tailored to specific country editions
